Register now!

Patients all over the world should benefit from the achievements of predictive medicine and the introduction of in silico clinical trials (ISCTs), which promise the accelerated and safe introduction of new products such as medical devices or pharmaceuticals to the market place. These concepts cannot be developed by academics or in industry alone, and ultimately they need to be accepted by regulatory agencies around the world. When regulators accept simulation augmented submissions, and agree upon a common model credibility assessment philosophy will patients benefit from the utilization of in silico medicine. 

The objective of the Avicenna Alliance International Working Group is the promotion of the benefits of predictive medicine and ISCTs through the global connections of experts from academia, industry, and regulatory agencies. Together we will work on developing objective standards, increasing confidence in in silico methods and their acceptance in support of regulatory approval process.

Avicenna Alliance news

Avicenna Alliance at BMES Conference in Washington- video available!

In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of...

find out more ›

FDA confirms its investment in modeling and simulation for improving drug development

Scott Gottlieb commissioner of the USA Food & Drug Administration has recently written an article for the FDA...

find out more ›

MEP Grossetête to visit NovaDiscovery site

On 7 July 2017 MEP Françoise Grossetête (EPP, France) will visit the new site of Avicenna Member, NovaDiscovery in Lyon...

find out more ›

Show all activites